Public-registry trials using Durvalumab that Eichor's radar has found — 2 trials. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC | AstraZeneca | High-risk Muscle Invasive Urothelial Carcinoma | PHASE3 | 160 |
| Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer | Taiho Pharmaceutical Co., Ltd. | Biliary Tract Cancer | PHASE3 | 21 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →